Roche (OTCQX:RHHBY) announced that it promoted Matt Sause to CEO of Roche Diagnostics.
Sause, 45, currently heads up Roche Diagnostics’ North America Region. His move to the corner office and to the company’s executive committee becomes effective Jan. 1, 2023.
The Basel, Switzerland-based company appointed current Roche Diagnostics CEO Thomas Schinecker to CEO, effective March 15, 2023.
“Matt Sause’s career at Roche has spanned twenty years in multiple countries across Asia, Latin America, Europe and North America in both the diagnostics and pharma divisions,” Schinecker said. “His combination of scientific knowledge with commercial experience makes him an excellent leader for the diagnostics division.”
The company’s board proposed the current CEO, Severin Schwan, as its new chair on March 14, 2023.
“Matt Sause has had an exceptional career with Roche and I am very pleased that we can once again internally appoint a leader of his caliber to become the next CEO Roche Diagnostics,” added Schwan.
Sause joined the company in the U.S. in 2002 as a senior molecular account manager. He progressed through various commercial general management and global product leadership roles. His positions spanned the diagnostics and pharma divisions in countries such as Japan, Ireland, Peru and South Korea.
In 2018, he moved to Genentech in the U.S. to serve as lifecycle leader for the Tecentriq monoclonal antibody medication for lung and head and neck cancers. This came just before he took over in his current role as CEO for Roche Diagnostics North America.
